BR0111827A - Vìrus de rna isolado, recombinantemente gerado, não segmentado, de sentido negativo, de filamento único do gênero morbillivìrus, composição imunogênica, método para imunizar um indivìduo para induzir proteção contra o dito vìrus, método para reduzir a repressão causada por uma proteìna v do gênero morbillivìrus, sequência de nucleotìdeos isolada, composição, e, método para produzir um morbillivìrus infeccioso - Google Patents
Vìrus de rna isolado, recombinantemente gerado, não segmentado, de sentido negativo, de filamento único do gênero morbillivìrus, composição imunogênica, método para imunizar um indivìduo para induzir proteção contra o dito vìrus, método para reduzir a repressão causada por uma proteìna v do gênero morbillivìrus, sequência de nucleotìdeos isolada, composição, e, método para produzir um morbillivìrus infecciosoInfo
- Publication number
- BR0111827A BR0111827A BR0111827-7A BR0111827A BR0111827A BR 0111827 A BR0111827 A BR 0111827A BR 0111827 A BR0111827 A BR 0111827A BR 0111827 A BR0111827 A BR 0111827A
- Authority
- BR
- Brazil
- Prior art keywords
- morbillivìrus
- isolated
- genus
- virus
- composition
- Prior art date
Links
- 241000712045 Morbillivirus Species 0.000 title abstract 6
- 241000700605 Viruses Species 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000003053 immunization Effects 0.000 title abstract 2
- 230000002163 immunogen Effects 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 230000002458 infectious effect Effects 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 239000002773 nucleotide Substances 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 241000712079 Measles morbillivirus Species 0.000 abstract 1
- 101710188314 Protein V Proteins 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 241001493065 dsRNA viruses Species 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18461—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21365500P | 2000-06-23 | 2000-06-23 | |
| PCT/US2001/019806 WO2002000694A2 (en) | 2000-06-23 | 2001-06-21 | Modified morbillivirus v proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0111827A true BR0111827A (pt) | 2003-05-20 |
Family
ID=22795965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0111827-7A BR0111827A (pt) | 2000-06-23 | 2001-06-21 | Vìrus de rna isolado, recombinantemente gerado, não segmentado, de sentido negativo, de filamento único do gênero morbillivìrus, composição imunogênica, método para imunizar um indivìduo para induzir proteção contra o dito vìrus, método para reduzir a repressão causada por uma proteìna v do gênero morbillivìrus, sequência de nucleotìdeos isolada, composição, e, método para produzir um morbillivìrus infeccioso |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6664066B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1292615B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2004513616A (cg-RX-API-DMAC7.html) |
| KR (1) | KR100885325B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1298738C (cg-RX-API-DMAC7.html) |
| AT (1) | ATE343589T1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2001267014B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0111827A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2409432C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1105842T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60124098T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1292615T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2273852T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL153004A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA02012256A (cg-RX-API-DMAC7.html) |
| PT (1) | PT1292615E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002000694A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE291925T1 (de) * | 2001-06-05 | 2005-04-15 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| DE10229872A1 (de) * | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| WO2004113517A2 (en) | 2003-06-09 | 2004-12-29 | Wyeth | IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA |
| DE102004042546A1 (de) * | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| JP2010507361A (ja) | 2006-07-31 | 2010-03-11 | キュアバック ゲーエムベーハー | 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸 |
| US20090017517A1 (en) * | 2007-07-13 | 2009-01-15 | Medimmune, Llc | Preparation of Negative-Stranded RNA Viruses by Electroporation |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| JP5721441B2 (ja) | 2008-01-31 | 2015-05-20 | キュアバック ゲーエムベーハーＣｕｒｅｖａｃ Ｇｍｂｈ | 免疫賦活剤／アジュバントとしての式（Ｉ）（ＮｕＧｌＸｍＧｎＮｖ）ａで表される核酸分子及びその誘導体 |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| EP2449113B8 (en) | 2010-07-30 | 2015-11-25 | CureVac AG | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| CN104471064B (zh) * | 2012-01-20 | 2018-11-02 | 中华人民共和国香港特别行政区政府 | 副粘病毒及其用途 |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| BR112016003361A2 (pt) | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
| WO2015149944A2 (en) | 2014-04-01 | 2015-10-08 | Curevac Gmbh | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| US9552559B2 (en) | 2014-05-06 | 2017-01-24 | Elwha Llc | System and methods for verifying that one or more directives that direct transport of a second end user does not conflict with one or more obligations to transport a first end user |
| US10458801B2 (en) | 2014-05-06 | 2019-10-29 | Uber Technologies, Inc. | Systems and methods for travel planning that calls for at least one transportation vehicle unit |
| US11100434B2 (en) | 2014-05-06 | 2021-08-24 | Uber Technologies, Inc. | Real-time carpooling coordinating system and methods |
| CN117010535A (zh) | 2014-05-06 | 2023-11-07 | 优步技术公司 | 用于要求至少一个运输车辆单元的出行计划的系统和方法 |
| WO2016009044A1 (en) * | 2014-07-18 | 2016-01-21 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Peptides including a binding domain of the viral phosphoprotein (p) subunit to the viral rna free nucleoprotein (n0) |
| US9911170B2 (en) | 2014-08-21 | 2018-03-06 | Uber Technologies, Inc. | Arranging a transport service for a user based on the estimated time of arrival of the user |
| US10685416B2 (en) | 2015-12-10 | 2020-06-16 | Uber Technologies, Inc. | Suggested pickup location for ride services |
| US10731998B2 (en) | 2017-11-05 | 2020-08-04 | Uber Technologies, Inc. | Network computer system to arrange pooled transport services |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0702085T4 (da) | 1994-07-18 | 2010-04-06 | Conzelmann Karl Klaus Prof Dr | Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus |
| EP0780475B2 (en) | 1995-08-09 | 2006-07-19 | SCHWEIZ. SERUM- & IMPFINSTITUT BERN | Process for the production of infectious negative-strand RNA viruses |
| WO1998013501A2 (en) * | 1996-09-27 | 1998-04-02 | American Cyanamid Company | 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales |
| DE69842165D1 (de) | 1997-05-23 | 2011-04-21 | Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services | Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen |
| IL138681A0 (en) | 1998-03-26 | 2001-10-31 | American Cyanamid Co | Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b |
-
2001
- 2001-06-21 PT PT01944623T patent/PT1292615E/pt unknown
- 2001-06-21 MX MXPA02012256A patent/MXPA02012256A/es active IP Right Grant
- 2001-06-21 KR KR1020027017494A patent/KR100885325B1/ko not_active Expired - Fee Related
- 2001-06-21 DK DK01944623T patent/DK1292615T3/da active
- 2001-06-21 CN CNB018116426A patent/CN1298738C/zh not_active Expired - Fee Related
- 2001-06-21 US US10/311,582 patent/US6664066B2/en not_active Expired - Fee Related
- 2001-06-21 BR BR0111827-7A patent/BR0111827A/pt not_active Application Discontinuation
- 2001-06-21 IL IL15300401A patent/IL153004A0/xx unknown
- 2001-06-21 ES ES01944623T patent/ES2273852T3/es not_active Expired - Lifetime
- 2001-06-21 AU AU2001267014A patent/AU2001267014B2/en not_active Ceased
- 2001-06-21 DE DE60124098T patent/DE60124098T2/de not_active Expired - Lifetime
- 2001-06-21 WO PCT/US2001/019806 patent/WO2002000694A2/en not_active Ceased
- 2001-06-21 CA CA2409432A patent/CA2409432C/en not_active Expired - Fee Related
- 2001-06-21 JP JP2002505816A patent/JP2004513616A/ja active Pending
- 2001-06-21 AU AU6701401A patent/AU6701401A/xx active Pending
- 2001-06-21 AT AT01944623T patent/ATE343589T1/de not_active IP Right Cessation
- 2001-06-21 EP EP01944623A patent/EP1292615B1/en not_active Expired - Lifetime
-
2006
- 2006-12-11 CY CY20061101780T patent/CY1105842T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60124098D1 (de) | 2006-12-07 |
| DK1292615T3 (da) | 2007-02-19 |
| DE60124098T2 (de) | 2007-04-05 |
| CA2409432C (en) | 2010-08-03 |
| JP2004513616A (ja) | 2004-05-13 |
| ES2273852T3 (es) | 2007-05-16 |
| CY1105842T1 (el) | 2011-02-02 |
| US6664066B2 (en) | 2003-12-16 |
| ATE343589T1 (de) | 2006-11-15 |
| WO2002000694A3 (en) | 2002-10-10 |
| EP1292615A2 (en) | 2003-03-19 |
| CN1437613A (zh) | 2003-08-20 |
| PT1292615E (pt) | 2007-01-31 |
| AU6701401A (en) | 2002-01-08 |
| AU2001267014B2 (en) | 2007-03-15 |
| WO2002000694A2 (en) | 2002-01-03 |
| CA2409432A1 (en) | 2002-01-03 |
| KR20030032971A (ko) | 2003-04-26 |
| MXPA02012256A (es) | 2003-04-25 |
| EP1292615B1 (en) | 2006-10-25 |
| CN1298738C (zh) | 2007-02-07 |
| US20030206925A1 (en) | 2003-11-06 |
| KR100885325B1 (ko) | 2009-02-25 |
| IL153004A0 (en) | 2003-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9712138A (pt) | Vìrus de rna isolado, vacina, processo para imunizr um indivìduo para induzir proteção contra um vìrus de rna não segmentado, sentido negativo, de filamento único, da ordem mononegavirales e para produzir vìrus de rna, molécula de ácido nucleico isolada e composição. | |
| McCrae et al. | The nature of the polypeptide encoded by each of the 10 double-stranded RNA segments of reovirus type 3 | |
| Tomcsányi et al. | Processing enzyme ribonuclease E specifically cleaves RNA I: an inhibitor of primer formation in plasmid DNA synthesis | |
| ATE343589T1 (de) | Modofiziertes morbillivirus v proteine | |
| Ritchey et al. | RNAs of influenza A, B, and C viruses | |
| Gottlieb et al. | In vitro packaging and replication of individual genomic segments of bacteriophage phi 6 RNA | |
| Frenkel et al. | Ribonucleic acid synthesis in cells infected with herpes simplex virus: controls of transcription and of RNA abundance | |
| Barik | Transcription of human respiratory syncytial virus genome RNA in vitro: requirement of cellular factor (s) | |
| Ulmanen et al. | In vitro translation of Uukuniemi virus-specific RNAs: identification of a nonstructural protein and a precursor to the membrane glycoproteins | |
| BRPI0411219A (pt) | seqüências de hbv e hcv conservadas úteis para silenciamento de gene | |
| Friesen et al. | Black beetle virus: messenger for protein B is a subgenomic viral RNA | |
| Russanova et al. | Adenovirus type 2 preferentially stimulates polymerase III transcription of Alu elements by relieving repression: a potential role for chromatin | |
| NO973685L (no) | Multi-tumor avvikende vekstgener | |
| TR200401186T4 (tr) | Rekombinant bir RNA-virüs oluşumunu yönlendirebilen nükleik asit sekansları içerikli suni kromozom yapıları. | |
| Thomas et al. | Alterations of transcription and translation in HeLa cells exposed to amino acid analogs | |
| Chinchar et al. | Functions of Sendai virus nucleocapsid polypeptides: enzymatic activities in nucleocapsids following cleavage of polypeptide P by Staphylococcus aureus protease V8 | |
| DE69927249D1 (de) | Induzierendes alphavirengen- expressionssystem | |
| Agranovsky et al. | Structure of the 3′ extremity of barley stripe mosaic virus RNA: Evidence for internal poly (A) and a 3′-terminal tRNA-like structure | |
| Epstein et al. | Defective interfering particle generated by internal deletion of the vesicular stomatitis virus genome | |
| Pettersson | 5'-Terminal nucleotide sequence of Semliki forest virus 18S defective interfering RNA is heterogeneous and different from the genomic 42S RNA. | |
| Friesen et al. | Early and late functions in a bipartite RNA virus: evidence for translational control by competition between viral mRNAs | |
| Lee et al. | Conserved regions in defective interfering viral double-stranded RNAs from a yeast virus | |
| Bonato et al. | Differential expression of heat‐shock proteins and spontaneous synthesis of HSP70 during the life cycle of Blastocladiella emersonii | |
| BR9815285A (pt) | Vetores alfavìrus para vacina de paramixovìrus | |
| Pinney et al. | Identification and characterization of a group of discrete initiated oligonucleotides transcribed in vitro from the 3'terminus of the N-gene of vesicular stomatitis virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |